Is TARS or TCRX more undervalued in 2026?

CirclFi compares Tarsus Pharmaceuticals, Inc. (TARS) and TScan Therapeutics, Inc. (TCRX) using 13 institutional-grade valuation models. TARS has a Quality of Company score of 6.2/10 while TCRX scores 6.4/10.

Which is a better buy — TARS or TCRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do TARS and TCRX valuations compare?

TARS at $59.54 and TCRX at $1.08 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

TARS vs TCRX Valuation Comparison 2026 — Intrinsic Value Analysis

TARS

Biotechnology

Tarsus Pharmaceuticals, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$59.54

Last close

Models

12/13

Active

TCRX

Biotechnology

TScan Therapeutics, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$1.08

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	TARS Fair Value	TARS Upside	TCRX Fair Value	TCRX Upside
Bayesian DCF	Intrinsic	$12.81	-78.5%	$0.71	-34.5%
Earnings Power Value	Intrinsic	$27.01	-56.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.67	-98.9%	$1.66	+53.8%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for TARS vs TCRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TARS vs TCRX — Which Stock Is More Undervalued?

TCRX scores higher with a 6.4/10 quality rating vs TARS's 6.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Tarsus Pharmaceuticals, Inc. (TARS) and TScan Therapeutics, Inc. (TCRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TARS currently trades at $59.54 with a QOC of 6.2/10, while TCRX trades at $1.08 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).